Rabasseda X
Thomson Reuters, Barcelona, Spain.
Drugs Today (Barc). 2013 Jun;49(6):411-7. doi: 10.1358/dot.2013.49.6.2002838.
As described in the following report, numerous research programs reported during this year's International Conference on Antiviral Research (ICAR) in San Francisco resulted in novel agents with antiviral activity against a number of viral pathogens, including programs aimed at compounds active against specific pathogens as well as broad preclinical research that identified compounds with putative activity against many virus families. As an example of the latter, a research program was reported that identified compounds with activity against HIV-1 and -2, herpes virus, influenza virus and Coxsackie virus (Dejmek, M. et al., Abst 35), while studies with Griffithsin, a red algae-derived protein with potent, broad antiviral activity against hepatitis C virus, coronavirus and Japanese encephalitis virus, among others, showed it also inhibited HIV, although only when the tight dimer structure is respected (Xue, J. et al., Abst 104).
正如以下报告所述，在今年于旧金山举行的国际抗病毒研究会议（ICAR）上报告的众多研究项目产生了对多种病毒病原体具有抗病毒活性的新型药物，包括针对对特定病原体有活性的化合物的项目以及确定了对许多病毒科具有假定活性的化合物的广泛临床前研究。作为后者的一个例子，有一个研究项目报告称确定了对HIV-1和-2、疱疹病毒、流感病毒和柯萨奇病毒有活性的化合物（德梅克，M.等人，摘要35），而对格里菲斯菌素（一种从红藻中提取的对丙型肝炎病毒、冠状病毒和日本脑炎病毒等具有强大、广泛抗病毒活性的蛋白质）的研究表明，它也能抑制HIV，不过只有在保持紧密二聚体结构时才行（薛，J.等人，摘要104）。
